Other News

Casana Receives FDA Clearance for Heart Health Smart Toilet Seat

Casana obtained FDA clearance for measuring Heart Rate (HR) and Oxygen Saturation (SpO2) Sensors embedded in the toilet seat enable effortless measurement of these vital signs Casana will pursue subsequent filings, including Systolic and Diastolic Blood Pressure (BP), with the target of an initial product market launch by the end […]

Anavex Life Sciences Announces Issuance of New U.S. Patent Expanding ANAVEX®2-73 (blarcamesine) Intellectual Property Portfolio for the Treatment of Hypertension

NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, announced today it […]

Cleerly Expands Executive Team With Appointment of New Chief Financial Officer and Executive Vice President of Regulatory Affairs Positions

Krissy Wright joins as CFO and Sandra Statz as EVP of Regulatory Affairs to Support Company’s Mission to Create a World Without Heart Attacks May 01, 2023 09:00 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced today it has […]

Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced that it has completed enrollment in the ALPACAR-360 phase 2 study of zerlasiran (SLN360) in subjects with elevated lipoprotein(a) (“Lp(a)”) […]

Therapeutic Solutions International Launches VasoSome Vascular Inc Based on Successful Treatment of Aortic Aneurysms using Patent Pending Exosome Therapy

Clinical Stage Company Expands Regenerative Medicine Franchise into 4 billion Dollar Aneurysm Market ELK CITY, Idaho–(BUSINESS WIRE)–Therapeutic Solutions International (TSOI) announced formation of a new spin-off company, VasoSome Vascular Inc, focused on treating the “living timebomb” condition of aortic aneurysms using stem cell derived exosomes. The aorta is the body’s […]

Abbott Completes Acquisition of Cardiovascular Systems, Inc.

ABBOTT PARK, Ill., April 27, 2023 /PRNewswire/ — Abbott (NYSE: ABT) today announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. The transaction provides Abbott with a complementary solution for treating vascular disease. CSI’s […]

ConcertAI’s TeraRecon Adds the Releases of an AI-Assisted Clinical Suite Solution, Neuro Suite to Provide Comprehensive Solutions for Neurological Disorders

CAMBRIDGE, Mass., April 28, 2023 /PRNewswire/ — ConcertAI’s TeraRecon, the advanced visualization and clinical AI SaaS category leader, has announced the release of its AI-driven clinical suite, Neuro Suite. Purpose-built for disease triage, differential diagnostic insights, and care activation in many neurological disease states such as neuro-oncology, dementia, multiple sclerosis, and more, […]

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress aXess graft demonstrated excellent patency, low rates of infection and re-intervention Data indicates a significant improvement in performance compared to standard hemodialysis access treatment EINDHOVEN, The Netherlands – 28 April 2023, Xeltis, a developer of transformative implants that enable the natural creation of living […]

CVRx Reports First Quarter 2023 Financial and Operating Results

MINNEAPOLIS, April 27, 2023 (GLOBE NEWSWIRE) — CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2023. Recent Highlights Totality of evidence from […]